Long-term prospects for Avidity strengthened significantly following its acquisition by Novartis, providing deep financial backing, robust global commercialization infrastructure, and expansive clinical resources to advance its proprietary antibody-oligonucleotide conjugate delivery platform. With major late-stage neuroscience programs targeting severe neuromuscular conditions moving through clinical trials, the enterprise is well-positioned for sustained scientific and market impact within the genetic medicine landscape.